Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease

Neurochemical Research

Volumn 35, Issue 10, 2010, Pages 1620-1627

  Ariza, Deborah ^a   Lima, Marcelo M S ^a   Moreira, Camila G ^a   Dombrowski, Patrícia A ^a   Avila, Thiago V ^a   Allemand, Alexandra ^a   B Mendes, Daniel A G ^a   Cunha, Claudio Da ^a   Vital, Maria A B F ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Animal models; Glutathione; LPS; Neuroinflammation

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; HOMOVANILLIC ACID; LIPOPOLYSACCHARIDE; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; GLUTATHIONE METABOLISM; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OPEN FIELD BEHAVIOR; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; GLUTATHIONE; LIPOPOLYSACCHARIDES; MALE; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TIME FACTORS;

ANIMALIA;

EID: 77957596565     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-010-0222-3     Document Type: Article

References (42)

1. A Castano AJ Herrera J Cano A Machado 2002 The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma J Neurochem 81 150 157 1:CAS:528:DC%2BD38XivVensbo%3D 10.1046/j.1471-4159.2002. 00799.x 12067227 (Pubitemid 34808862)
2. MM Iravani E Syed MJ Jackson LC Johnston LA Smith P Jenner 2005 A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets Eur J Neurosci 21 841 854 10.1111/j.1460-9568.2005. 03915.x 15787691 (Pubitemid 40461038)
3. N Simola M Morelli AR Carta 2007 The 6-hydroxydopamine model of Parkinson's disease Neurotox Res 11 151 167 1:CAS:528:DC%2BD2sXotFymu7c%3D 10.1007/BF03033565 17449457
4. C Capitelli A Sereniki MM Lima AB Reksidler S Tufik MA Vital 2008 Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats Eur J Pharmacol 594 101 108 1:CAS:528:DC%2BD1cXhtVynurzK 10.1016/j.ejphar.2008.07.022 18674531
5. C Da Cunha MH Silva S Wietzikoski EC Wietzikoski MM Ferro I Kouzmine NS Canteras 2006 Place learning strategy of substantia nigra pars compacta-lesioned rats Behav Neurosci 120 1279 1284 10.1037/0735-7044.120.6.1279 17201473 (Pubitemid 46058703)
6. C Da Cunha EC Wietzikoski P Dombrowski M Bortolanza LM Santos SL Boschen E Miyoshi 2009 Learning processing in the basal ganglia: a mosaic of broken mirrors Behav Brain Res 199 157 170 10.1016/j.bbr.2008.10.001 18977393
7. E Lane S Dunnett 2007 Animal models of Parkinson′s disease and L-dopa induced dyskinesia: how close are we to the clinic? Psychopharmacology (Berl) 199 303 312 10.1007/s00213-007-0931-8
8. MMS Lima ML Andersen AB Reksidler MABF Vital S Tufik 2007 The role of the substantia nigra pars compacta in regulating sleep patterns in rats PLoS ONE 2 e513 10.1371/journal.pone.0000513 17551593
9. MMS Lima A Braga Reksidler S Marques Zanata H Bueno Machado S Tufik MA Vital 2006 Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats Brain Res 1101 117 125 1:CAS:528:DC%2BD28XntVWjt7Y%3D 10.1016/j.brainres.2006.05.016 (Pubitemid 44036768)
10. MMS Lima AB Reksidler MA Vital 2009 The neurobiology of the substantia nigra pars compacta: from motor to sleep regulation J Neural Transm Suppl 73 135 145 1:CAS:528:DC%2BC3cXnvFGqu78%3D 20411774
11. C Monaca C Laloux JM Jacquesson P Gele X Marechal R Bordet A Destee P Derambure 2004 Vigilance states in a parkinsonian model, the MPTP mouse Eur J Neurosci 20 2474 2478 10.1111/j.1460-9568.2004.03694.x 15525288 (Pubitemid 39472409)
12. AB Reksidler MMS Lima P Dombrowski ML Andersen SM Zanata R Andreatini S Tufik MABF Vital 2008 Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease J Neurosci Methods 167 268 277 1:CAS:528:DC%2BD2sXhsVequr3E 10.1016/j.jneumeth.2007.08.024 17931705 (Pubitemid 350235638)
13. AB Reksidler MMS Lima SM Zanata HB Machado C da Cunha R Andreatini S Tufik MABF Vital 2007 The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats Eur J Pharmacol 560 163 175 1:CAS:528: DC%2BD2sXislKhs7g%3D 10.1016/j.ejphar.2006.12.032 17320073 (Pubitemid 46341312)
14. MT Tadaiesky PA Dombrowski CP Figueiredo E Cargnin-Ferreira C Da Cunha RN Takahashi 2008 Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease Neuroscience 156 830 840 1:CAS:528:DC%2BD1cXhtlSgsrnO 10.1016/j.neuroscience.2008.08.035 18817851
15. G Dutta P Zhang B Liu 2008 The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery Fundam Clin Pharmacol 22 453 464 1:CAS:528:DC%2BD1cXht1Gmt7%2FK 10.1111/j.1472-8206.2008.00616.x 18710400
16. SL Byler GW Boehm JD Karp RA Kohman AJ Tarr T Schallert TM Barth 2009 Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6 J mice Behav Brain Res 198 434 439 1:CAS:528: DC%2BD1MXhvFGqs7g%3D 10.1016/j.bbr.2008.11.027 19070633
17. N Hamaue A Ogata M Terado K Ohno S Kikuchi H Sasaki K Tashiro M Hirafuji M Minami 2006 Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat induced by Japanese encephalitis virus Neurochem Res 31 1451 1455 1:CAS:528:DC%2BD28Xht1Oht77N 10.1007/s11064-006-9197- 5 17103330 (Pubitemid 44900585)
18. A Ogata K Tashiro S Nukuzuma K Nagashima WW Hall 1997 A rat model of Parkinson's disease induced by Japanese encephalitis virus J Neurovirol 3 141 147 1:STN:280:DyaK2s3msFaguw%3D%3D 10.3109/13550289709015803 9111176
19. MF Beal 2003 Mitochondria, oxidative damage, and inflammation in Parkinson's disease Ann N Y Acad Sci 991 120 131 1:CAS:528:DC%2BD3sXmtVCku78%3D 10.1111/j.1749-6632.2003.tb07470.x 12846981
20. A Hald J Lotharius 2005 Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 193 279 290 1:CAS:528: DC%2BD2MXjslKjtbo%3D 10.1016/j.expneurol.2005.01.013 15869932 (Pubitemid 40616179)
21. AB Reksidler MMS Lima P Dombrowski GF Barnabé ML Andersen S Tufik MABF Vital 2009 Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease J Neural Transm Suppl 73 259 268 1:CAS:528:DC%2BC3cXnvFKjsrY%3D 20411784
22. A Zager ML Andersen MM Lima AB Reksidler RB Machado S Tufik 2009 Modulation of sickness behavior by sleep: the role of neurochemical and neuroinflammatory pathways in mice Eur Neuropsychopharmacol 19 589 602 1:CAS:528:DC%2BD1MXnvVWnu78%3D 10.1016/j.euroneuro.2009.03.005 19394204
23. Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates, 5th edn. Academic Press, San Diego
24. P Teismann K Tieu DK Choi DC Wu A Naini S Hunot M Vila V Jackson-Lewis S Przedborski 2003 Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration Proc Natl Acad Sci U S A 100 5473 5478 1:CAS:528: DC%2BD3sXjs1yitbc%3D 10.1073/pnas.0837397100 12702778 (Pubitemid 36542729)
25. P Teismann M Vila DK Choi K Tieu DC Wu V Jackson-Lewis S Przedborski 2003 COX-2 and neurodegeneration in Parkinson's disease Ann N Y Acad Sci 991 272 277 1:CAS:528:DC%2BD3sXmtVCrsrw%3D 10.1111/j.1749-6632.2003.tb07482.x 12846993
26. PS Whitton 2007 Inflammation as a causative factor in the aetiology of Parkinson's disease Br J Pharmacol 150 963 976 1:CAS:528:DC%2BD2sXkt1Chsr8%3D 10.1038/sj.bjp.0707167 17339843 (Pubitemid 46628616)
27. T Wyss-Coray L Mucke 2000 Ibuprofen, inflammation and Alzheimer disease Nat Med 6 973 974 1:CAS:528:DC%2BD3cXms12ltrc%3D 10.1038/79661 10973311
28. A Castano AJ Herrera J Cano A Machado 1998 Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system J Neurochem 70 1584 1592 1:STN:280:DyaK1c7otFOhsg%3D%3D 10.1046/j.1471-4159.1998.70041584.x 9580157
29. AJ Herrera A Castano JL Venero J Cano A Machado 2000 The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system Neurobiol Dis 7 429 447 1:CAS:528:DC%2BD3cXmtVGnt7c%3D 10.1006/nbdi.2000.0289 10964613
30. A Abuirmeileh A Harkavyi A Kingsbury R Lever PS Whitton 2009 The CRF-like peptide urocortin greatly attenuates loss of extracellular striatal dopamine in rat models of Parkinson's disease by activating CRF(1) receptors Eur J Pharmacol 604 45 50 1:CAS:528:DC%2BD1MXhsFOms7k%3D 10.1016/j.ejphar.2008.11.009 19026631
31. PF Hsieh LG Chia DR Ni LJ Cheng YP Ho SF Tzeng MH Chang JS Hong 2002 Behavior, neurochemistry and histology after intranigral lipopolysaccharide injection Neuroreport 13 277 280 1:CAS:528:DC%2BD38XnsFKrsrY%3D 10.1097/00001756-200203040-00006 11930122
32. DY Choi M Liu RL Hunter WA Cass JD Pandya PG Sullivan EJ Shin HC Kim DM Gash G Bing 2009 Striatal neuroinflammation promotes Parkinsonism in rats PLoS One 4 e5482 10.1371/journal.pone.0005482 19424495
33. J Zhang DM Stanton XV Nguyen M Liu Z Zhang D Gash G Bing 2005 Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits Neuroscience 135 829 838 1:CAS:528:DC%2BD2MXhtVymtrrN 10.1016/j.neuroscience.2005.06.049 16165292 (Pubitemid 41407745)
34. RL Hunter N Dragicevic K Seifert DY Choi M Liu HC Kim WA Cass PG Sullivan G Bing 2007 Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system J Neurochem 100 1375 1386 1:CAS:528:DC%2BD2sXjt1Grs7w%3D 10.1111/j.1471-4159.2006.04327.x 17254027
35. C Da Cunha MS Gevaerd MA Vital E Miyoshi R Andreatini R Silveira RN Takahashi NS Canteras 2001 Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia Behav Brain Res 124 9 18 1:CAS:528:DC%2BD3MXksVylt7Y%3D 10.1016/S0166-4328(01)00211-X 11423161 (Pubitemid 32567554)
36. CL Zuch VK Nordstroem LA Briedrick GR Hoernig AC Granholm PC Bickford 2000 Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion J Comp Neurol 427 440 454 1:STN:280:DC%2BD3M%2FmvV2ksA%3D%3D 10.1002/1096-9861(20001120)427:3<440::AID- CNE10>3.0.CO;2-7 11054705
37. MM Ferro MI Bellissimo JA Anselmo-Franci ME Angellucci NS Canteras C Da Cunha 2005 Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations J Neurosci Methods 148 78 87 1:CAS:528:DC%2BD2MXhtVynt7rM 10.1016/j.jneumeth.2005.04.005 15939479 (Pubitemid 41423461)
38. B Liu JW Jiang BC Wilson L Du SN Yang JY Wang GC Wu XD Cao JS Hong 2000 Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide J Pharmacol Exp Ther 295 125 132 1:CAS:528:DC%2BD3cXnt1ygtbY%3D 10991969
39. TL Perry DV Godin S Hansen 1982 Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33 305 310 1:STN:280: DyaL3s7kt1aktA%3D%3D 10.1016/0304-3940(82)90390-1 7162692 (Pubitemid 13119539)
40. TL Perry VW Yong 1986 Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients Neurosci Lett 67 269 274 1:STN:280:DyaL283osFKluw%3D%3D 10.1016/0304-3940(86)90320-4 3737015 (Pubitemid 16038336)
41. P Jenner CW Olanow 1998 Understanding cell death in Parkinson's disease Ann Neurol 44 S72 S84 1:CAS:528:DyaK1cXmtFGktr4%3D 9749577
42. Z Ling Y Zhu C Tong JA Snyder JW Lipton PM Carvey 2006 Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally Exp Neurol 199 499 512 1:CAS:528: DC%2BD28XmtlGmt70%3D 10.1016/j.expneurol.2006.01.010 16504177 (Pubitemid 43928976)